Ovid Therapeutics

Ovid Therapeutics

A biotechnology company specializing in creating therapeutics for neurological disorders. It was founded in 2014 and is located in New York City.

About

Ovid Therapeutics is a New York-based company with a focus on developing medicines for patients living with rare neurological disorders. The company partners with patient advocacy groups and foundations in order to better understand the community for whom it is working.It also collaborates with other biotechnology and pharmaceutical companies to develop its therapeutics, such as Takeda and Lundbeck.

Product

The company has multiple therapeutics that are in the process of going through clinical trials. It focuses on specific neurological disorders and develops drugs to treat those disorders. One such disorder is Angelman syndrome. The company is conducting clinical trials for both adolescents and adults for therapeutics such as gaboxadol.

FAnother disorder for which the company is developing therapeutics is Fragile X syndrome. The clinical trials also used the therapeutic gaboxadol. The studies for CDKL5 deficiency disorder and chromosome 15q duplication syndrome used the therapeutic soticlestat to seek results.

Timeline

August 2020

Ovid Therapeutics partners with Angelini for research.

August 2020

The University of Connecticut partners with Ovid Therapeutics for rare-disease research.

2014

Ovid Therapeutics is founded.

Funding rounds

Funding round
Funding type
Funding round amount (USD)
Funding round date
Investment
Ovid Therapeutics Series B round, August 2015
75,000,000
August 11, 2015
3 Results
Page 1 of 1
Results per page:
Powered by Golden Research Engine

People

Name
Role
LinkedIn

Further reading

Title
Author
Link
Type
Date

Documentaries, videos and podcasts

Title
Date
Link

Companies

Company
CEO
Location
Products/Services

News

Title
Author
Date
Publisher
Description
Nick Paul
July 13, 2020
FierceBiotech
Ovid Therapeutics has offloaded the European rights to OV101 in a genetic nervous system disorder to Italy's Angelini Pharma. Angelini is paying $20 million upfront to secure a license to a drug that is due to come through a phase 3 trial in Angelman syndrome by the end of the year.

References

Golden logo
Text is available under the Creative Commons Attribution-ShareAlike 4.0; additional terms apply. By using this site, you agree to our Terms & Conditions.